Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for Revelumide tablets, and will conduct clinical trials for prostate cancer in the near future. Specifically, a multicenter, randomized, double-blind, placebo-controlled phase III clinical study on the efficacy and safety of reverumide combined with androgen deprivation therapy (ADT) versus placebo plus ADT for high-risk localized or high-risk biochemical recurrence (BCR) prostate cancer after radical surgery/radiotherapy.

Revelumide tablets are second-generation AR inhibitors. Compared with first-generation AR inhibitors, they have a stronger AR inhibitory effect and have no agonistic effect. The company's Revilumide tablets were approved for marketing in 2022 to treat patients with metastatic hormone-sensitive prostate cancer (MHSPC) with a high tumor burden.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.